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Abstract
Several ESAT-6-based vaccines have been widely studied in different animal models, presenting potent
ability to induce both cellular and humoral responses. As ESAT-6 is a well-characterized mycobacterial antigen,
its capacity to induce immune responses in a nonhuman primate model has been evaluated. The immunization
of recombinant ESAT-6 (rESAT-6) in Aotus nancymaae monkeys has elicited a strong cellular response, not
just to rESAT-6, but also to the native protein present in Mycobacterium tuberculosis culture filtrate proteins
measured as [3H]thymidine incorporation in lymphocyte proliferation assays. High humoral response was also
observed, having antibody titers of 1:12,800 directed towards rESAT-6. The proteins multi-epitope nature
was further demonstrated since several peptide sequences were specifically recognized at both cellular and
humoral level. The high immunogenicity observed, as well as the relatively high characterization of the Aotus
immune system at molecular level, are two advantage to propose Aotus nancymaae as animal model for
studying M. tuberculosis infection; however, our results reveal an animal-to-animal variation in response to
vaccination, this could be a disadvantage.
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Resumen
La única vacuna disponible contra la tuberculosis es la cepa Mycobacterium bovis BCG, que ofrece una
eficacia protectiva variable (0%-80%), siendo urgente un nuevo agente profiláctico. Se han evaluado diver-
sos candidatos a vacuna contra este patógeno, en los modelos animales de experimentación convencionales
(murino, cobayo, conejo), obteniéndose información básica sobre el efecto de la vacuna en la carga bacterial
frente a un reto infeccioso, así como también la reducción o prevención de la patología en los pulmones u
otros órganos blanco; además de los aspectos relacionados con la respuesta inmune hacia el Mycobacterium
tuberculosis. Los primates no humanos tienen ventajas sobre los modelos convencionales en la evaluación de
vacunas, de hecho se ha verificado el comportamiento de agentes terapéuticos en humanos después de haber
sido medida la capacidad protectiva de éstos en monos con tuberculosis inducida. Los primates mas estudia-
dos en la infección por micobacterias son el cynomulgus, y el rhesus, observándose que estos animales
mantienen la infección en un estado subclínico, muy similar a la tuberculosis humana donde el 90% de la
población infectada mantiene la infección en un estado latente. Dado que el modelo animal debe semejar el
15
Introduction
The only available anti-tuberculosis vaccine is based
on the Mycobacterium bovis BCG strain giving va-
riable protective efficacy (0%-80%), making
developing a new prophylactic agent an urgent priority
(1-3). Great advances have been made in knowledge
regarding Mycobacterium tuberculosis, including
deciphering the genomes sequence (4), bioinformatics
analysis in silico, proteomic studies directed towards
characterizing and determining mycobacterial protein
function and immunogenicity (5-8), the
mycobacteriums cell wall structure and morphology
(9,10) as well as the role of the main cellular
populations, cytokines and chemokines involved in
Mycobacterium tuberculosis infection (11,12).
Possible vaccine candidates against this pathogen
have been developed having diverse characteristics
such as recombinant vaccines, auxotroph vaccines and
DNA vaccines (13-19). Orme I. et. al have reported
that about 50% of the 170 candidates or combinations
of candidates which have been tested fall into the
subunit vaccine category, reflecting increasing
knowledge regarding protein make-up of the bacillus
and increased access to techniques helping identify
immunogenic proteins (20). These candidate vaccines
have been especially evaluated in mouse, guinea-pig
and rabbit models which have provided basic
information about the vaccines effect on bacterial
load regarding infectious challenge and reducing or
preventing pathology in the lungs and other target
organs as well as some aspects related to the immune
response to Mycobacterium tuberculosis (21-25).
Nonhuman primates appear to have significant
advantages over conventional laboratory animals in
terms of modelling pulmonary tuberculosis for purposes
of vaccine evaluation (26). The usefulness of tuber-
culosis induced in monkeys for developing different
therapeutic agents has been verified when predicting
these drugs behaviour in humans (27,28). Non-human
primate studies have demonstrated that these animals
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comportamiento de las proteínas estudiadas en el ser humano, el mono Aotus puede representar ventajas en
la investigación de tuberculosis por ser un primate con aproximadamente un 90% de similitud al humano en
cuanto a las moléculas del sistema inmune estudiadas hasta hoy. La proteína ESAT-6 de (early secretory
antigenic target 6 kD) de Mycobacterium tuberculosis es un componente minoritario del filtrado de cultivo
de corto tiempo (CFP), ha sido genética y químicamente caracterizada e induce una potente respuesta
inmunogénica del tipo TH1. Este antígeno es secretado durante la fase inicial de crecimiento siendo fuerte-
mente reconocido por animales y humanos infectados por Mycobacterium tuberculosis, este hecho hace
que su inclusión en una futura vacuna anti-tuberculosis por subunidades y en pruebas de inmunodiagnóstico.
En este trabajo se estudió la respuesta inmune del mono Aotus frente al antígeno micobacteriano ESAT-6 en
forma recombinante (rESAT-6). El antígeno fue inmunizado junto con el adyuvante Montanide 720 producien-
do una fuerte respuesta humoral y celular, no solo hacia rESAT-6 sino también hacia la proteína nativa pre-
sente en el filtrado de medio de cultivo de Mycobacterium tuberculosis. La respuesta celular fue medida
por la incorporación de [3H]timidina en ensayos de linfoproliferación. La respuesta humoral se analizó por
ensayos de ELISA e inmunoblot, obteniéndose altos títulos de anticuerpos (hasta de 1:12,800) dirigidos rESAT-
6. Se demostró la naturaleza multiepitope de este antígeno ya que en general péptidos que mapean la proteína
fueron específicamente reconocidos tanto a nivel celular como humoral. Se observó además variación en la
respuesta a la vacunación entre animal y animal, siendo una desventaja para un modelo de experimentación
en cuanto a la predicción de la respuesta. Este estudio se constituye en un primer paso de evaluación del
mono Aotus como modelo animal en tuberculosis.
Palabras claves: Mono Aotus, modelo animal, Mycobacterium tuberculosis ESAT-6, respuesta inmune.
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Figure 1. rESAT-6 characterizing. (A) Clonation, expression and purification of rESAT-6: gel electrophoresis, immunoblot, HPLC chromatography
and circular dichroism. (B) Maldi-Tof mass spectrometry.
A.
B.
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are susceptible to tuberculosis when challenged
(29,30).
According to reports, a significant percentage of
Macaca fasicularis (cynomolgus monkeys)
challenged with low M. tuberculosis doses were able
to maintain the infection in a sub-clinical state, very
similar to human tuberculosis where 90% of the
infected population have latent infection. Other studies
have shown that non-human primates can be partially
protected by vaccination with BCG and display a
delayed-type hypersensitivity (DTH) to prior contacts
with mycobacterial antigens (27,31-32). M. tubercu-
losis culture filtrate protein (CFP) immunogenicity and
safety in rhesus and baboon monkeys have been
investigated; results showed a short-lived immunity
at both humoral and cellular responses, with low IFNg
production levels (33,34).
ESAT-6 (early secretory antigenic target 6 kD) is
a short-term culture filtrate component; it is a genetic
and chemically characterized protein inducing potent
TH1 responses (35-41). This antigen is secreted during
mycobacterial initial growth phase, being strongly
recognized in different species infected with M. tu-
berculosis (humans, bovines and mice); this means
that its inclusion in a future anti-tuberculosis subunit
vaccine and in current immuno-diagnostic tests is
well-founded (39,42-44).
The Aotus owl monkeys immune response to
rESAT-6 is studied in this work. Immunization with
the recombinant antigen together with Montanide 720
adjuvant produces very good humoral and cell-specific
responses, even for a long period of time. It was
observed at humoral immune response that ESAT-6
protein present in Mycobacterium tuberculosis CFP
was recognized by Aotus sera immunized with rESAT-
6. Efficient in vitro stimulation of lymphocytes with
both recombinant protein and CFP was determined in
proliferation assays, indicating that a cell-mediated
immune response was being generated.
Materials and Methods
Immunogen and antigens.
rESAT-6 was expressed in DH5a -pQE30
prokaryote system (QIAGEN), was purified by
affinity chromatography using a Metal Chelate
Affinity-Ni2+ resin and imidazol gradient. rESAT-6
was characterized by immunoblot, HPLC (reverse
phase and size exclusion chromatography), Maldi-Tof
mass spectrometry and circular dichroism, Figure 1.
The Mycobacterium bovis BCG live vaccine
(Lyophilized, Inter Vax, Canada) was also used as
reactivity control for in vivo experiments.
CrudeMycobacterium tuberculosis H37Rv culture
filtrate protein (CFP) produced by the National
Institutes of Health, National Institute of Allergy and
Infectious Diseases (Contract N01-AI-75320, kindly
donated by Dr. J. Belisle at Colorado State University)
was used in the in vitro immunological assays. ESAT-
Table I. ESAT-6 synthetic peptide sequences
*FIDIC peptide number
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6 protein 20-amino-acid long peptides were synthesized
by solid phase methodology (53), purified by HPLC
and characterized by mass spectrometry. Peptide
numbers and sequences are shown in Table I.
Animals.
A total of 15 healthy Aotus nancymaae owl
monkeys (having been previously orally deparasitized
with Ivermectin) were selected based on immunoblots
of the sera analyzed having minimum or null
mycobacterial recognition (Mycobacterium tubercu-
losis H37Rv lysate). Monkeys were kept at our
institutes experimental primate station in Leticia
(Amazon) in accordance with CCAC (Committee on
Care and Use of Laboratory Animals, US) guidelines
and Colombian National Institute of Health guidelines
for the use of laboratory animals, supervised by the
ColombianWildlife Corporation (CorpoAmazonia).
The presence of mycobacteria in monkeys housed
at the colony was evaluated by randomly taken
samples. One hundred samples from different sources,
gastric lavage, faecal material, soil, food and drinking-
water were thus analyzed. Advantage was taken of
the anaesthesia (35mg/kg weight ketamin, 0.1mg/Kg
atropine and 1 mg/Kg diazepam, applied intra-
muscularly) required for some procedures carried out
on the 30 Aotus for also performing gastric lavage using
a size 6 Levin probe (54). The samples were
decontaminated by Petroffs technique (55). Ziehl
Neelsen (ZN) staining, and culturing in Bactec
MIGT960 system and solid medium (Middlebrook
7H10) (for 6 weeks at 37°C) were then carried out.
The tuberculin test was done in the eyelids of 15 Aotus
previously positive for acid-fast bacilli (AFB) and/or
rejected from the study during the selection process
due to having some type of specific mycobacterial
antigen recognition. A 100ml tuberculin dose (PPD
RT23 SSI, Swtatens Serum Institute, Copenhagen) was
intra-dermally administered.
Immunization.
Five monkeys were selected for each immunogen
(Table II). 100mg rESAT-6 in PBS (137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4 and 1.4 mM KH2P04)
per monkey-dose were applied to the first group. The
second group received only Mycobacterium bovis
BCG; this was reconstituted in PBS, applied at 50mg
per dose. The third group corresponded to the placebo
(PBS plus adjuvant). Immunogens were emulsified
with Montanide ISA 720 adjuvant (SEPPIC-France)
in a 70:30 ratio by sonication when being applied.
Aotus were immunized subcutaneously with 200ml
emulsion in the abdomen three times at 30 day intervals
(days 0, 30 and 60). Blood was collected immediately
prior to the first injection, on day 30 and every month
on three occasions. Monkeys were physically
monitored for 180 days for developing local and
systemic reactions.
Table II. Immunized Aotus monkey groups
Immunogens  were dissolved in PBS (I, II, and III) and emulsified 30:70 with Montanide ISA720
adjuvant (I and III).
M. bovis BCG was not emulsified in Montanide  ISA720 adjuvant
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Antibody response.
For enzyme-linked Immunosorbent assays
(ELISAs), the antigens were diluted in PBS at 10mg/
well (CFP) and 1 mg/well (rESAT-6 and peptides) and
used for coating microtiter wells; the wells were
blocked with 3% BSA. Serum samples (previously
adsorbed with E. coli lysate proteins) were added at
diferent dilutions; horseradish peroxidase (HRP)-
conjugated goat anti-Aotus IgG (produced by FIDIC)
was added to each well as second antibody. The
reaction was developed using TMB Microwell
Peroxidase Substrate System, A620nm was read on a
Labsystems Multiskan MJ ELISA reader (56).
For Western Blot analysis, CFP were separated
by sodium dodecylsulphate-polyacrylamide gel
electrophoresis (SDS-PAGE), under reducing
conditions on a 10-15% gradient gel. rESAT-6 was
separated by 14% SDS-PAGE in Tris-Tricine system.
The gels were electrophoretically transferred to
nitrocellulose membrane (Trans-Blot Bio Rad).
Blocking buffer (1% nonfat milk-TBS (10mMTrisHCl
pH7.5, 150mM NaCl)-0.05% Tween 20) was used
for saturating non-specific sites. Single nitrocellulose
strips with nearly 50mg CFP or 1 mg rESAT-6 were
incubated with monkey serum diluted 1:100 in blocking
buffer. Strips were incubated with Alkaline
phosphatase (AP)-labelled goat anti-Aotus IgG, BCIP/
NBT (Promega) was used for detection (57).
Cellular proliferative response.
Monkeys were splenectomized on day 150 after
the study was begun. Lymphocytes were obtained by
preparing single-cell suspensions from spleens and
then purified by Ficoll-Hypaque (ICN Lympho
separation medium) gradient centrifugation. Cells were
washed and suspended in RPMI 1640 medium
containing HEPES, L-glutamine, antibiotic-antimycotic
and 20% autologous serum. 100ml cell suspension
containing 106 cells were plated onto 96-well flat-
bottom plates, together with antigen (13). CFP (10mg/
ml), rESAT-6 or peptides (1mg/ml) were used as
antigens and 5mg/ml phytohemagglutinin (PHA,
DIFCO) or RPMI 1640 as positive control and non-
stimulated control respectively. Each stimulation was
performed in triplicate wells. Plates were incubated
at 37°C in 5% CO2for72 h. [
3H]thymidine (1mCi/well;
Amersham) was added for the final 16-18 hours
incubation. Cells were harvested onto filters (Glass
Fibre Strips 240-1, Cambridge Tech.) by using a cell
harvester; filters were dried and cells were counted
in a scintillation counter. Results are reported as
stimulation index (SI): a two-fold increase in counts
per minute over non-stimulated control were
considered positive .
Results
Mycobacterial presence.
No signs of tuberculous infection were observed;
few alcohol-resistant bacilli were found in those
randomly-chosen samples taken; only 8 positive
specimens were isolated in the population analyzed in
BACTEC culture and verified by ZN: 4 came from
gastric lavage, 1 from soil and 3 from faecal mate-
rial. DNA isolated from cultured samples was further
analyzed by PCR (54), being negative for M. tuber-
culosis complex mycobacteria (data not shown). The
tuberculin test was done in the eyelids of 15 Aotus
previously positive for AFB and/or rejected from the
study during the selection process due to having some
type of specific mycobacterial antigen recognition; no
induration or positive reaction was detected 24 to 72
hours following application.
Aotus selection and immunization.
Two parameters were taken into account in the
process of selecting animals for this study: optimum
state of health (indicated by clinical evaluation) and
minimum or null sera recognition of M. tuberculosis
H37Rv proteins inWestern blot assay. Sera adsorption
with E. coli proteins allowed specific recognition of
mycobacterial proteins which is why this procedure
was done prior to the immunoblot and ELISA
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analyses. Monkeys were immunized on three times,
presenting satisfactory clinical analysis. No evidence
was seen of nodules or erythema at the application
site in animals immunized with rESAT-6; similar
results were obtained in the placebo monkeys. Aotus
group II received a single dose of BCG; nodulations
were observed which were immobile to the touch at
the application site compromising skin and
subcutaneous tissue, Table II.
Humoral immune response.
Immunoblot and ELISA were used for determining
rESAT-6 and CPF antibody recognition by monkey
sera.Antisera obtained from group I animals at various
times after the first and subsequent immunizations were
able to strongly bind rESAT-6 dose-dependently for
most animals, Figure 2A. Except for Monkey 5, which
displayed very low recognition (data not shown), native
ESAT-6 present in CFPwas also recognized, even from
the first bleeding. There was less recognition intensity,
however, out of the whole protein pattern found in CFP
(more than 100 proteins), specificity was confirmed as
the only band being recognized had the same molecular
mass as ESAT-6, Figure 2B.
Figure 2. Western blot analysis showing the binding of antibodies from immunized Aotus monkeys with rESAT-6. (A) Results of immunodetection
in rESAT-6. (B) Mycobacterium tuberculosis crude CFP (B). Primary antibodies 1:100 dilution sera. Assay controls: a* strip incubated with
anti-polyHistidine (Sigma), then anti-mouse IgG-PA (ICN.); c* strip incubated with anti-Ag85B, then anti-rabbit IgG-PA (ICN); b* and c* reagent
control for A and B, respectively.
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Figure 3. ELISA assay for IgG antibodies generated by immunization with rESAT. (A) CFP and rESAT. (B) 5 peptides mapping ESAT-6. 620nm
absorbance delta, corresponding to the value obtained in each bleeding less pre-immune sera absorbance of each monkey regarding each
antigen. Primary antibodies 1:100 dilution. Each bar represents the mean of triplicate values.
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ELISA assays corroborated the foregoing; it was
determined that the rESAT-6 antigen binding titer
became progressively increased until obtaining titers
between 1:800 and 1:12,800 for bleeding III (after 90
days). Antibody titers measured in CFPwere generally
constant in the different immunizations, 1:100 being
the lowest value (Figure 3A). Studying the different
peptide sequences mapping the protein showed varied
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Figure 4. Proliferative responses of spleen-derived lymphocytes from Aotus immunized with rESAT-6 (Monkeys 1 and 2) and BCG (Monkey
6). [3H]thymidine incorporation in response to in vitro stimulation with rESAT-6, the pool of ESAT-6 peptides, CFP and PHA (positive control)
were measured 90 days after final immunization. Data are reported as SIs (fold stimulation over that of cells incubated in just medium). Results
shown are representative of the immunized population. Each bar represents the mean of triplicate values ± sem
recognition for the different animals. Except for
Monkey 5 (having no appreciable antibody titer values
to any particular peptide), the other antisera
recognized sequences throughout the whole protein,
amino-terminal portion (NH2-ter) not being recognized
(Figure 3B). No significant rESAT-6 antibody titers
were observed when sera from animals immunized
with BCG or placebo were tested (data not shown).
Cellular immune response.
Cellular proliferative responses were assessed using
animals spleen lymphocytes. Figure 4 showsproliferation
levels induced by rESAT-6, the pool of peptidesmapping
the protein, CFP and PHA in two representative
experiments of rESAT-6 immunized animals (Monkeys 1
and 2).All immunizedmonkeys developed a proliferative
cellular response to CFP, including monkeys immunized
withBCG;Figure 4 showsMonkey 6 lymphoproliferation
resultswhichwere typical ofAotus immunizedwithBCG.
In all cases proliferation induced by PHA was greater
than that found with the other antigens (recombinant and
peptides), including that displayed by placebo monkey
lymphocytes. Recombinant protein and peptide pool
stimulationwas specific in those animals immunizedwith
just rESAT-6. The results show strong stimulation of
antigens, even though being different for each monkey.
SI values ranged from 15 to 34 for rESAT-6; 8 to 28 for
the peptide pool; and 10 to 29 for CFP.
The proliferative response of cells from rESAT-6
immunized animals stimulated with peptides mapping
the protein was lower than that observed when
stimulation with the recombinant protein was carried
out, Table IV. Contrary to what happens with humo-
ral response, several monkeys recognized the proteins
NH2-ter portion (peptide 12033) simulta-neously with
the carboxy-terminal region (COOH-ter), as observed
in Monkeys 2 and 3. The other Aotus recognized the
(COOH-ter) region with peptides 12036 and 12037.
None of the peptides tested was recognized by
Monkey 5. Cells stimulated with peptides from the
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proteins middle region (12034 and 12035) did not
present any appreciable proliferation.
Discussion
Several years ago it was shown that the low mass
secreted ESAT-6 protein was a molecule associated
with memory effector TH1 lymphocytes in long-lived
immunity to tuberculosis, having high interferon gamma
(IFNg) production levels (40,58). It is strongly
recognized inM. tuberculosis-infected humans, leading
to research into its use in diagnostic kits reflected in
high percentages of sensitivity and specificity for
infection caused by tuberculosis (44, 59-60). Studies
aimed at vaccine development carried out in animals,
including mice, guinea pigs, bovines and non-human
primates have described strong humoral and cellular
recognition. Several B- and T-epitopes have been
recognized throughout the protein, depending on the
species analyzed (43,61-63).
Immunogenicity and protection-inducing levels have
been explored in diverse preparations such as DNA
and recombinant ESAT-6 vaccines (13-14,17,64-65).
These candidates have been able to induce cellular
TH1 response and protection similar to that presented
by BCG. Subunit vaccines (in which ESAT-6 potential
has been evaluated) have also been reported;
determining the modulating effect of the immune
response of the adjuvant used in the immunization
process, depending on the antigen. One study has
shown that the ESAT-6-DDA combination (dimethyl
dioctadecyl ammoniumbromide) does not induce any
appreciable immune response in the murine model.
When MPL (monophosphoryl lipidA) is incorporated
into the preparation in different combinations, strong
adjuvant activity can be observed for both cellular and
humoral immune responses (42). The data presented
in different reports indicate that protective immunity
determined for different ESAT-6 vaccines is at the
same level as BCG, a relevant result for a single M.
Table III. rESAT-6 binding antibody titers obtained by ELISA assay
Table IV. ESAT-6 peptide-stimulated splenocyte proliferation assays
Monkey 4 died before the experiment ended.
Positive values were considered as having SI>2 (shown in bold and underlined).
Each result represents the mean of triplicate values ± sem.
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tuberculosis antigen; these results show high humo-
ral and cellular response when recombinant protein
was administered using Montanide 720 as adjuvant.
Montanide 720 is a metabolizable mannide oleate in
oil solution adjuvant which has been recently approved
for use in humans. Aotus immunized with rESAT-6
or the placebo did not present nodules (as observed
with animals immunized with BCG).
Different reports have indicated that ESAT-6
contains numerous epitopes recognized by a high
percentage of individuals, depending on the sensitivity
of the assay used (59,61,66). Different peptide
sequences involved in humoral recognition were
observed in Aotus monkeys, where almost the whole
protein participates in antibody production.
Interestingly none of the immunized animals sera
recognized the recombinant antigen NH2-ter portion.
Likewise, low recognition of ESAT-6 NH2-ter region
peptides by antibodies in tuberculous non-human pri-
mate sera (cynomulgus macaques, rhesus macaques,
African Green monkeys) has been recently
demonstrated in a study using overlapping peptides
spanning the ESAT-6 protein sequence, while an
important recognition towards the COOH-ter portion
is observed even early in infection (63). At cellular
response level, sequences mainly comprising the
COOHter fraction have induced proliferation in all
immunized monkeys, while two of the immunized
monkeys are able to respond towards the NH2-ter also.
Similar results have been reported in previous studies
using human cells (41,66-68). Cellular and humoral
in vitro immune response stimulation were lower
whenever peptides mapping ESAT-6 protein were
used, suggesting that either conformational epitopes
were present or that some epitopes were missing due
to the use of non-overlapped peptides.
The Aotus nancymaae monkey has been
recommended by the World Health Organization
(WHO) as a model for malaria vaccine candidate
evaluation (69-70). This has favored immune system
molecule research leading to a high percentage of
homology with humans being elucidated. Recent data
has shown 78% to 95% homology for MHC-II
molecules (histocompatibility Class-II complex) (45-
52,71) which have been declared as having great
importance in tuberculosis infection (23-24).
Lymphocytes proliferative in vitro response to
mitogens in Aotus nancymaae has been analyzed,
showing that it varies from monkey to monkey
depending on the particular mitogen assessed (72);
this was also seen in the present work. Varied cellular
and humoral recognition was determined amongst
different monkeys and even to different antigens;
however, the results show that positive recognition
values are antigen-specific, having no ambiguity
regarding immune response.
It has been reported that all primates are suscepti-
ble to tuberculosis, although differences between
species exist (e.g. Old World primate species such as
rhesus monkeys are very sensitive to infection whilst
New World species such as squirrel monkeys appear
to be less susceptible) (27). There have been few
reports recently regarding tuberculosis in NewWorld
Monkeys, even more so in the wild. A study isolating
and identifying mycobacteria in NewWorld primates
maintained in captivity identifiedM. chelonae subsp.
abscessus in one of the two Aotus sp. analyzed (54).
Few monkeys were found to be positive for
mycobacteria in the current study; all isolated
mycobacteria were non-pathogenic, althoughAmazon
province (Colombia) is tuberculosis pulmonary disease
endemic area (73).
The tuberculin test was done in Aotus previously
positive for AFB and/or having some type of
mycobacterial antigen recognition; no induration or
positive reaction was detected. This result (together
with positive recognition of mycobacterial antigens)
suggests that such animals were not infected by
pathogenic mycobacteria, that low AFB detection in
the analyzed population was due to Aotus having been
in contact with environmental mycobacteria and that
shared epitope cross-recognition was being generated.
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Aotus develop a strong immune response when they
were immunized with a mycobacterial antigen in a
recombinant protein form (rESAT-6) emulsified with
Montanide 720 as adjuvant. Immune response had
multi-epitope characteristics and was seen to be
different among the monkeys analyzed as similar
human studies, but this behavior is a disadvantage for
a reliable experimental model because de responses
are not enough predictable. A significant number
animals were analized and not any monkey were found
to be positive for pathogenic mycobacteria or positive
reaction to tuberculin test.
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